@PlusTherapeutics

@PlusTherapeutics has been a member of Linktree for 5 years and joined in March 2021. The social media accounts linked to from @PlusTherapeutics are: Facebook, Instagram, YouTube, LinkedIn, Email, X. Besides social media accounts, PlusTherapeutics has populated their site with A Letter from Our CEO: Redefining How CNS Cancer Is Solved, Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding - Plus Therapeutics, Inc., Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - Plus Therapeutics, Inc., Targeted Radiotherapeutics | Life Science Daily News, CNSide at Best of ASCO Austin | Free CME Event for Healthcare Professionals | CNSide® Diagnostics, The Future of Brain Cancer Care: Combining Diagnostics and Targeted Radiation Therapy - YouTube, Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic - Plus Therapeutics, Inc., Advances In Precision Delivery In CNS Oncology, The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment - BioSpace, Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory - Plus Therapeutics, Inc., Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases - Plus Therapeutics, Inc., ISPOR Poster, Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology - Plus Therapeutics, Inc., Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - Plus Therapeutics, Inc., Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ - Plus Therapeutics, Inc., Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution - Plus Therapeutics, Inc., Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline - Plus Therapeutics, Inc., Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas - Plus Therapeutics, Inc., Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption - Plus Therapeutics, Inc., Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives - Plus Therapeutics, Inc., Notice of 2026 Annual Meeting of Stockholders to Be Held on May 14, 2026, Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40% - Plus Therapeutics, Inc., Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ - Plus Therapeutics, Inc., Plus Therapeutics, ReSPECT™ Clinical Trials, RESPECT-GBM Clinical Trial, RESPECT-LM Clinical Trial, 2026 Corporate Deck, Empowered Patient Podcast: AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics, Leptomeningeal Metastases (LM) Education Poster.